Kite Licenses Antibodies and Establishes Collaboration With Teneobio in Multiple Myeloma
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Business Wire
-- Kite and Teneobio will Collaborate on Next-Generation Dual-Targeting CAR T Therapies in Multiple Myeloma Utilizing UniAb® Antibodies -- SANTA MONICA, Calif. & NEWARK, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), and Teneobio, Inc. announced the companies have entered into a license and collaboration agreement through which Kite will receive exclusive rights to certain antibodies directed to B-cell maturation antigen (BCMA). The fully human variable heavy chain of one such antibody is currently undergoing clinical evaluation in a chimeric antigen receptor (CAR) format for the treatment of patients with multiple myeloma in a Phase 1 clinical trial at the National Cancer Institute. Kite and Teneobio will also collaborate on the discovery of antibodies directed to four additional targets, using Teneobio’s proprietary Human Heavy-Chain Antibodies (UniAb®) platform, to be used in CAR T cell therapies for multiple myeloma and other cancers.This press release features
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights [Yahoo! Finance]Yahoo! Finance
- Autoimmune Hepatitis Diagnosis and Treatment Market Size to Reach USD 19.15 Bn by 2032 [Yahoo! Finance]Yahoo! Finance
- Winn Awards Help Physicians Solve Healthcare Disparities [Yahoo! Finance]Yahoo! Finance
- Top Pictet Fund Manager Sees Biotech Stocks Joining AI-Euphoria [Yahoo! Finance]Yahoo! Finance
- Top Pictet Fund Manager Sees Biotech Stocks Joining AI-Euphoria [BNN Bloomberg (Canada)]BNN Bloomberg
GILD
Earnings
- 2/6/24 - Miss
GILD
Sec Filings
- 3/28/24 - Form ARS
- 3/28/24 - Form DEF
- 3/28/24 - Form DEFA14A
- GILD's page on the SEC website